Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that sells automated microbial quality control systems to pharmaceutical manufacturers. Revenue comes from four streams: Growth Direct system sales, proprietary consumables, LIMS connection and other software, and services. The company pursues a land-and-expand model, placing initial systems at customer sites and then selling additional units across multiple suites and global facilities. As of December 31, 2025, 75% of the top 20 global pharmaceutical companies by revenue were customers. Gross margin improved from (24.4)% in FY2023 to (0.4)% in FY2024 to 3.1% in FY2025, with the company still operating at a net loss. Net cash used in operating activities was $31.1 million in FY2025 versus $44.2 million in FY2024. Primary manufacturing is in Lowell, Massachusetts, with a backup consumables facility in Lexington, Massachusetts, and third-party logistics in Oss, Netherlands. The company holds 12 granted U.S. patents and 72 issued foreign patents covering the Growth Direct platform, with expirations between 2032 and 2045.

Revenue model

Capital equipment sales (Growth Direct systems), recurring proprietary consumables, LIMS and software licenses, and post-sale services. System revenue is transactional and concentrated among a small group of customers each period; consumables provide recurring pull-through revenue on a per-system basis.

Products and services

Growth Direct automated microbial quality control platform, proprietary consumables (growth media and cassettes), LIMS connection software, and after-sales services including validation support.

Customers and end markets

Pharmaceutical manufacturers requiring microbial quality control testing in production environments. 75% of the top 20 global pharmaceutical companies by revenue were customers as of the FY2025 10-K filing. The majority of customers operate multiple Growth Direct systems, and over 40% have deployed systems across multiple facility locations.

Value-chain role

Equipment and consumables supplier to pharmaceutical manufacturing quality control operations. Sits between raw materials suppliers and pharmaceutical production, providing automated testing systems that replace or supplement traditional manual microbial testing methods.

Geographic exposure

Primary operations in Lowell and Lexington, Massachusetts. Sales through direct and indirect channels in North America, Europe, and Asia-Pacific. Third-party logistics warehouse in Oss, Netherlands. Foreign patent coverage includes Australia, Canada, China, Europe, India, Japan, and Mexico. Subject to EU GDPR and UK GDPR through a German subsidiary.

Source: SEC 10-K, filed 2026-03-12

Industry: Laboratory Analytical Instruments Peers: Absci Corp Alpha Teknova Inc Nautilus Biotechnology Inc Bruker Cellular Analysis, Inc. Champions Oncology Inc Harvard Bioscience Inc Science 37 Holdings, Inc. Personalis Inc Singular Genomics Systems, Inc. Thermo Fisher Scientific Inc